CN104428024A - 鼻部递送装置 - Google Patents
鼻部递送装置 Download PDFInfo
- Publication number
- CN104428024A CN104428024A CN201380021179.2A CN201380021179A CN104428024A CN 104428024 A CN104428024 A CN 104428024A CN 201380021179 A CN201380021179 A CN 201380021179A CN 104428024 A CN104428024 A CN 104428024A
- Authority
- CN
- China
- Prior art keywords
- housing
- grip element
- part section
- outstanding
- delivery apparatus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012384 transportation and delivery Methods 0.000 title claims abstract description 49
- 210000003928 nasal cavity Anatomy 0.000 claims abstract description 18
- 239000000126 substance Substances 0.000 claims abstract description 11
- 210000001331 nose Anatomy 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- 210000000214 mouth Anatomy 0.000 claims description 9
- 238000007664 blowing Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 14
- 210000002850 nasal mucosa Anatomy 0.000 description 6
- 206010028735 Nasal congestion Diseases 0.000 description 5
- 210000003695 paranasal sinus Anatomy 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 208000030880 Nose disease Diseases 0.000 description 3
- 239000000850 decongestant Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 210000001989 nasopharynx Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 206010001229 Adenoidal hypertrophy Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010019375 Helicobacter infections Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000026344 Nasal disease Diseases 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- 201000003462 adenoid hypertrophy Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000000492 nasalseptum Anatomy 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 241000158526 Nasalis Species 0.000 description 1
- 102000012547 Olfactory receptors Human genes 0.000 description 1
- 108050002069 Olfactory receptors Proteins 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical class O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010226 intestinal metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000010352 nasal breathing Effects 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 208000005923 otitis media with effusion Diseases 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 230000009745 pathological pathway Effects 0.000 description 1
- 229940030215 pitocin Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 208000024036 serous otitis media Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/586—Ergonomic details therefor, e.g. specific ergonomics for left or right-handed users
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0618—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0625—Mouth
Abstract
一种鼻部递送装置,包括:壳体(15);用于配合到一对象的鼻腔的鼻承(17);该对象在使用中通过其吹气的口承(19);和物质供应单元(21),该物质供应单元包括从壳体的一端延伸出的致动件(23)且该物质供应单元被手动操作以将物质递送到该对象的鼻腔;其中,该外壳包括布置在该外壳的一端的握柄部段(27),致动件从该外壳的一个基底端延伸出,所述握柄部段包括远侧的第一部分(28)和近侧的第二部分(31),该远侧的第一部分包括至少一个突出的握柄元件(29),通过该突出的握柄元件该对象在操作致动件期间握住壳体,该近侧的第二部分提供该对象的手指可位于其中的凹部(33),所述凹部促成递送装置在该对象手中的正确取向。
Description
技术领域
本发明涉及用于递送物质到一对象的鼻气道的鼻部递送装置和方法,该物质尤其是呈悬浮液或溶液形式的液体,或含有药剂尤其是全身用药物或局部用药物的粉末,或疫苗。
背景技术
参见图5,鼻气道1包括被鼻中隔隔开的两个鼻腔,其中鼻气道1包括如鼻窦口3和泪管口5的多个口以及嗅觉细胞并且衬有鼻粘膜。鼻气道1可以与鼻咽7、口腔9和下气道11连通,其中鼻气道1通过口咽膜13的开闭有选择地与鼻咽7的前区和口腔9连通。通常也称为软腭的膜13在闭合位置以实线示出,可通过在口腔9中提供一定正压来达到该闭合位置,例如通过口腔9呼气来实现,在打开位置用虚线来表示。
有许多鼻部疾病需要治疗。一种这样的状况是鼻炎,具体为鼻粘膜炎,其可能是过敏性或非过敏性的,通常与感染有关并妨碍正常的鼻功能。例如,通常10%至20%的人群患有鼻气道的过敏性和非过敏性炎症,此时,鼻甲海绵组织的鼻充血、流泪、稀鼻涕分泌、打喷嚏和发痒是最常见的症状。人们将会理解,鼻充血阻碍鼻呼吸,促使口呼吸,导致打呼噜和睡眠障碍。其它鼻部疾病包括从鼻窦突出的鼻息肉、增殖体肥大、分泌性中耳炎、鼻窦疾病和嗅觉减弱。
在某些鼻部疾病的治疗中,局部给药是有利的,尤其是在鼻粘膜是主要的病理途径的情况下,例如在治疗或缓解鼻充血的治疗中,通常局部给服的药剂包括减充血剂、抗组织胺类、色甘酸类、类固醇和抗生素。现在,在多种已知的抗炎药中,局部类固醇已显示出对鼻充血有效。局部减充血剂也被建议用于减缓鼻充血。用局部减充血剂、类固醇和抗菌剂来进行增殖体肥大和慢性分泌性中耳炎的治疗尽管有争议,但也已经被提出了。此外,局部给药已用于治疗或至少减轻鼻咽前区、鼻窦和咽鼓管的炎症。
药剂也可以通过鼻道进行全身递送,鼻道为药物如激素(如后叶催产素和降血钙素)和止痛剂(如抗偏头痛组合物)的全身递送提供很好的给药路径,因为鼻粘膜的高血液流速和大表面积利于提供快速的全身性吸收。
还期望鼻服给药对需要快速起作用的药剂如止痛剂、止吐剂、胰岛素、抗癫痫剂、镇静剂和催眠剂和其它药物(如心血管药)的给送是有利的。可以想到,鼻服给药将以与注射类似但比口服给药快许多的速度快速起效。确实,对许多严重状况的治疗来说,鼻服给药比口服给药有利,因为胃潴留会在口服给药后减缓起效速度。
还可以预料到,鼻服给药可以为通过现代生物技术制成的蛋白质和肽的给服提供有效递送路径。对于这种物质,肠新陈代谢和肝脏首过效应对可靠且成效划算的递送产生重大障碍。
此外可以预料到,使用本发明的鼻服递送技术的鼻服给药将证明在许多常见的神经疾病如阿尔茨海默氏症、帕金森氏症、精神病和脑内感染的治疗中是有效的,这些疾病的治疗用现有技术是做不到的。本发明的鼻服递送技术允许递送到嗅区,该嗅区位于鼻腔的上侧区并且表示在此能绕过血脑屏障(BBB)并实现与脑脊髓液(CSF)和脑连通的唯一区域。
还可以预料到,本发明的鼻服递送技术将允许疫苗的有效服送。
除了药剂服送外,用液体尤其是盐溶液冲洗鼻粘膜通常用于除去颗粒和分泌物以及改善鼻粘膜的粘液绒毛的活性。这些溶液可以与活性药物结合使用。
对于任何药物的服送,精确和可靠的给药是关键的,但是对于治疗窗窄的强效药、带有潜在严重反作用的药以及用于治疗严重并威胁生命状况的药的给送是特别重要的。对于一些状况,例如在糖尿病的情况下,关键的是根据特定情况个性化给药。对糖尿病和甚至许多其它状况,给药优选基于实际实时测量。当前,最常用的是血样,但是对于一些状况已提出对对象呼气的分子分析来替代血分析。呼吸分析当前用于一些状况如幽门螺旋杆菌感染的诊断,幽门螺旋杆菌感染会导致胃溃疡。
国际专利申请公开号WO-A-2000/051672公开一种递送装置,该递送装置用于通过鼻腔的双向流(也就是气流从一个鼻孔进,绕过鼻中隔后缘后,按相反方向从另一个鼻孔出)来递送物质尤其是药剂。这种双向气流有利地起到刺激鼻粘膜的感觉神经的作用,因此使对象适应递送并提供更舒服的递送状况。
发明内容
本发明的目的是提供用于将物质送到一对象鼻腔的鼻部递送装置和方法,尤其是相对简单且可机械操作的递送装置。
在一个方面,本发明提供一种用于递送物质到一对象鼻腔的鼻部递送装置,该递送装置包括:壳体;用于配合到该对象鼻腔的鼻承;该对象在使用中通过其呼气的口承;和物质供应单元,该物质供应单元包括从壳体的一端延伸出的致动件且该物质供应单元被手动操作以将物质递送到该对象的鼻腔;其中该壳体包括主体部段和布置在主体部段的一端的握柄部段,物质供应单元的致动件从该主体部段的基底端延伸出,该握柄部段包括远侧的第一部分和近侧的第二部分,该远侧的第一部分包括至少一个突出的握柄元件,通过该突出的握柄元件该对象在操作物质供应单元的致动件期间握住壳体,该近侧的第二部分提供该对象的手指可位于其中的凹部,凭借该凹部促成递送装置在该对象手中的正确取向。
在一个实施例中,该主体部段包括细长部段。
在一个实施例中,该至少一个突出的握柄元件是围绕或大体围绕壳体周边延伸的周向唇部。
在另一个实施例中,握柄部段的远侧部分包括第一和第二突出的握柄元件,其在壳体的相对侧突出,而没有中间元件。
在一个实施例中,第一和第二突出的握柄元件在与口承的轴线共面的轴线上对齐。
在另一个方面,本发明提供一种将物质送到一对象鼻腔的方法,该方法包括以下步骤:提供鼻部递送装置,该装置包括:壳体;用于配合到该对象鼻腔的鼻承;该对象通过其呼气的口承;和物质供应单元,该物质供应单元包括从壳体的一端延伸出的致动件且该物质供应单元被手动操作以将物质递送到该对象的鼻腔;其中该壳体包括主体部段和布置在主体部段的一端的握柄部段,物质供应单元的致动件从该主体部段的基底端延伸出,该握柄部段包括远侧的第一部分和近侧的第二部分,该远侧的第一部分包括至少一个突出的握柄元件,通过该突出的握柄元件该对象在操作物质供应单元的致动件期间握住壳体,该近侧的第二部分提供该对象的手指可位于其中的凹部;将鼻承配合到该对象的鼻腔;将口承放置在对象的口腔中;以及握住壳体以使该对象的手指位于壳体的相对侧的凹部,并邻近该至少一个突出的握柄元件,从而促成递送装置在该对象手中的正确取向以实现递送装置的操作。
在一个实施例中,该主体部段包括细长部段。
在一个实施例中,该至少一个突出的握柄元件是围绕或大体围绕壳体周边延伸的周向唇部。
在另一个实施例中,握柄部段的远侧部分包括第一和第二突出的握柄元件,其在壳体的相对侧突出,而没有中间元件。
在一个实施例中,第一和第二突出的握柄元件在与口承的轴线共面的轴线上对齐。
附图说明
现在本发明的优选实施例将仅以示例的方式参考附图描述,其中:
图1示出了根据本发明的第一实施例的鼻部递送装置的透视图;
图2(a)和图2(b)示出了图1的鼻部递送装置的正交侧视图;
图3示出了根据本发明的第二实施例的鼻部递送装置的透视图;
图4(a)和图4(b)示出了图3的鼻部递送装置的正交侧视图;和
图5示意性示出了人类对象上呼吸道的解剖图。
具体实施方式
图1和图2示出了根据本发明的第一实施例的鼻部递送装置。
该鼻部递送装置包括壳体15、用于配合到一对象鼻腔的鼻承17、该对象在使用中通过其呼气的口承19、和物质供应单元21,该物质供应单元21包括从壳体15的一端延伸出的致动件23且该物质供应单元21被手动操作以将物质递送到该对象的鼻腔。
该壳体15包括主体部段25,在此实施例中该主体部段是细长部段,物质供应单元21的致动件23从该主体部段的一个基底端延伸出。
该壳体15进一步包括布置在主体部段25的一端的握柄部段27。
该握柄部段27包括远侧的第一部分28和近侧的第二部分31,该远侧的第一部分28包括至少一个突出的握柄元件29,通过该突出的握柄元件29对象在操作物质供应单元21的致动件23期间握住壳体15,通常是在手指之间握住壳体15,该近侧的第二部分31提供对象的手指可位于其中的凹部或腰部33。
在此实施例中,突出的握柄元件29是围绕或大体围绕壳体15周边延伸的周向凸缘或唇部。
本发明的发明人已意识到提供邻近凸缘元件或唇部元件29的凹部或腰部33可促成递送装置在使用者手中的正确取向,只要使用者被要求使递送装置以特定方式在鼻腔中定向,就可实现递送装置的最佳性能。
图3和图4示出了根据本发明的第二实施例的鼻部递送装置。
本实施例的递送装置与上述第一实施例非常相似,因此为了避免不必要的重复描述,将仅详细描述区别。
在本实施例中,握柄部段27的远侧部分28包括第一和第二突出的握柄元件29a、29b,其在壳体15的相对侧突出,而没有中间元件。在本实施例中,第一和第二突出的握柄元件29a、29b在与口承的轴线共面的轴线上对齐。
本发明的发明人已意识到这种构型可促成递送装置在使用者手中被握住时的正确的回转取向,只要使用者被要求使递送装置以特定方式在鼻腔中定向,可实现递送装置的最佳性能。
最后,人们将会理解本发明已经描述了其多个优选实施例并且能够在不背离由所附权利要求书限定的本发明的范围的情况下以多种不同方式修改。
Claims (10)
1.一种用于递送物质到一对象鼻腔的鼻部递送装置,该递送装置包括:
壳体;
用于配合到该对象的鼻腔的鼻承;
该对象在使用中通过其吹气的口承;和
物质供应单元,该物质供应单元包括从壳体的一端延伸出的致动件且该物质供应单元被手动操作以将物质递送到该对象的鼻腔;
其中,该外壳包括主体部段和布置在该主体部段的一端的握柄部段,该物质供应单元的致动件从该主体部段的基底端延伸出,该握柄部段包括远侧的第一部分和近侧的第二部分,该远侧的第一部分包括至少一个突出的握柄元件,通过该突出的握柄元件该对象在操作物质供应单元的致动件期间握住壳体,该近侧的第二部分提供该对象的手指可位于其中的凹部,由此该凹部促成递送装置在该对象手中的正确取向。
2.根据权利要求1所述的递送装置,其中,所述主体部段包括细长部段。
3.根据权利要求1或2所述的递送装置,其中,所述至少一个突出的握柄元件是围绕或大体围绕所述壳体的周边延伸的周向唇部。
4.根据权利要求1或2所述的递送装置,其中,所述握柄部段的远侧部分包括第一和第二突出的握柄元件,该第一和第二突出的握柄元件在所述壳体的相对侧突出,而没有中间元件。
5.根据权利要求4所述的递送装置,其中,所述第一和第二突出的握柄元件在与口承的轴线共面的轴线上对齐。
6.一种将物质送到一对象鼻腔的方法,该方法包括以下步骤:
提供鼻部递送装置,该装置包括:壳体;用于配合到该对象鼻腔的鼻承;该对象通过其呼气的口承;和物质供应单元,该物质供应单元包括从壳体的一端延伸出的致动件且该物质供应单元被手动操作以将物质递送到该对象的鼻腔;其中该壳体包括主体部段和布置在该主体部段的一端的握柄部段,该物质供应单元的致动件从该主体部段的基底端延伸出,该握柄部段包括远侧的第一部分和近侧的第二部分,该远侧的第一部分包括至少一个突出的握柄元件,通过该突出的握柄元件该对象在操作物质供应单元的致动件期间握住壳体,该近侧的第二部分提供该对象的手指可位于其中的凹部;
将鼻承配合到该对象的鼻腔;
将口承放置在该对象的口腔中;并且
握住壳体以使该对象的手指位于壳体的相对侧的凹部,并邻近该至少一个突出的握柄元件,从而促成递送装置在该对象手中的正确取向以实现递送装置的操作。
7.根据权利要求6所述的方法,其中,所述主体部段包括细长部段。
8.根据权利要求6或7所述的方法,其中,所述至少一个突出的握柄部段是围绕或大体围绕所述壳体的周边延伸的周向唇部。
9.根据权利要求6或7所述的方法,其中,所述握柄部段的远侧部分包括第一和第二突出的握柄元件,该第一和第二突出的握柄元件在所述壳体的相对侧突出,而没有中间元件。
10.根据权利要求9所述的递送装置,其中,所述第一和第二突出的握柄元件在与口承的轴线共面的轴线上对齐。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261603089P | 2012-02-24 | 2012-02-24 | |
US61/603089 | 2012-02-24 | ||
PCT/EP2013/053748 WO2013124493A1 (en) | 2012-02-24 | 2013-02-25 | Nasal delivery devices |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104428024A true CN104428024A (zh) | 2015-03-18 |
CN104428024B CN104428024B (zh) | 2018-06-01 |
Family
ID=47915159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380021179.2A Active CN104428024B (zh) | 2012-02-24 | 2013-02-25 | 鼻部递送装置 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10179216B2 (zh) |
EP (1) | EP2817053B1 (zh) |
JP (1) | JP6382723B2 (zh) |
CN (1) | CN104428024B (zh) |
CA (1) | CA2865355C (zh) |
DK (1) | DK2817053T3 (zh) |
ES (1) | ES2683865T3 (zh) |
HK (1) | HK1207010A1 (zh) |
IN (1) | IN2014DN07610A (zh) |
MX (1) | MX358062B (zh) |
PL (1) | PL2817053T3 (zh) |
RU (1) | RU2644293C2 (zh) |
WO (1) | WO2013124493A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114602046A (zh) * | 2022-05-10 | 2022-06-10 | 纳索菲德(上海)制药技术有限公司 | 向鼻腔嗅区递送药液的装置及其使用方法 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0215270D0 (en) | 2002-07-02 | 2002-08-14 | Optinose As | Nasal devices |
GB0311570D0 (en) | 2003-05-20 | 2003-06-25 | Optinose As | Delivery device and method |
GB0319119D0 (en) | 2003-08-14 | 2003-09-17 | Optinose As | Delivery devices |
GB0320171D0 (en) | 2003-08-28 | 2003-10-01 | Optinose As | Delivery devices |
GB0420513D0 (en) | 2004-09-15 | 2004-10-20 | Optinose As | Powder delivery devices |
GB0503738D0 (en) | 2005-02-23 | 2005-03-30 | Optinose As | Powder delivery devices |
AU2006335994A1 (en) | 2006-01-19 | 2007-07-26 | Optinose As | Nasal administration |
GB0604444D0 (en) | 2006-03-06 | 2006-04-12 | Optinose As | Nasal devices |
GB0605799D0 (en) | 2006-03-23 | 2006-05-03 | Optinose As | Nasal delivery devices |
GB2438834A (en) | 2006-06-08 | 2007-12-12 | Optinose As | Intranasal protein administration |
GB2440316A (en) | 2006-07-25 | 2008-01-30 | Optinose As | Nasal inhaler with scrubber |
GB0623732D0 (en) | 2006-11-28 | 2007-01-10 | Optinose As | Powder delivery devices |
GB0623731D0 (en) | 2006-11-28 | 2007-01-10 | Optinose As | Delivery device |
GB0623728D0 (en) | 2006-11-28 | 2007-01-10 | Optinose As | Delivery devices |
GB2448193A (en) | 2007-04-05 | 2008-10-08 | Optinose As | Nasal delivery device |
GB2448183A (en) | 2007-04-05 | 2008-10-08 | Optinose As | Nasal powder delivery device |
GB0719299D0 (en) | 2007-10-03 | 2007-11-14 | Optinose As | Nasal delivery devices |
GB201015371D0 (en) | 2010-09-14 | 2010-10-27 | Optinose As | Nasal delivery |
US9949923B2 (en) | 2011-03-15 | 2018-04-24 | Optinose As | Nasal delivery |
PL2817054T3 (pl) | 2012-02-24 | 2020-12-14 | Optinose As | Donosowe urządzenia podające |
KR20150004327A (ko) | 2012-02-24 | 2015-01-12 | 옵티노즈 에이에스 | 경비 투여 장치 |
EP2817053B1 (en) | 2012-02-24 | 2018-05-30 | Optinose AS | Nasal delivery devices |
US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
USD761951S1 (en) | 2013-05-23 | 2016-07-19 | Optinose As | Nosepiece unit |
EP2868334B1 (de) | 2013-11-05 | 2017-01-11 | Benedict Gerber | Nasendusche |
SG11201703794TA (en) | 2014-11-19 | 2017-06-29 | Optinose As | Intranasal administration |
US20230064327A1 (en) | 2020-01-22 | 2023-03-02 | Seelos Therapeutics, Inc. | Reducing side effects of nmda antagonists |
KR20220151265A (ko) | 2021-05-06 | 2022-11-15 | 김대황 | 비강 약물 투여 장치 및 방법 |
WO2022241214A1 (en) | 2021-05-14 | 2022-11-17 | Seelos Therapeutics, Inc. | Methods of using nmda receptor antagonists |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020046751A1 (en) * | 2000-04-14 | 2002-04-25 | John Macrae | Nasal inhaler |
CN200994915Y (zh) * | 2006-12-27 | 2007-12-26 | 游世规 | 一种鼻腔清洗器 |
CN101918061A (zh) * | 2007-10-03 | 2010-12-15 | 奥普蒂诺斯公司 | 鼻腔递送装置 |
WO2011153406A2 (en) * | 2010-06-04 | 2011-12-08 | The Government of the United States of America as represented by the Secretary of Health and Human Services, Centers for Disease Control and Prevention | Nasal aerosol delivery system |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US605436A (en) | 1898-06-07 | Inhaler | ||
US642748A (en) | 1899-02-23 | 1900-02-06 | Arthur Manners | Inhaler. |
US746749A (en) | 1903-03-18 | 1903-12-15 | George E Seidel | Nasal medicator. |
TR199700669T1 (xx) | 1995-01-23 | 1998-02-21 | Direct-Haler A/S | �nhalat�r. |
US5797392C1 (en) | 1996-01-22 | 2001-01-09 | Direct Haler As | Inhaler |
DE69825995T2 (de) | 1997-05-27 | 2005-09-08 | Direct-Haler A/S | Inhalator für pulverförmige medikamente |
GB0121568D0 (en) | 2001-09-06 | 2001-10-24 | Optinose As | Nasal delivery device |
GB0114272D0 (en) | 2001-06-12 | 2001-08-01 | Optinose As | Nasal delivery device |
AU766410B2 (en) | 1999-03-03 | 2003-10-16 | Optinose As | Nasal delivery device |
GB0015309D0 (en) | 2000-06-21 | 2000-08-16 | Djupesland Per G | Apparatus |
ZA200306564B (en) | 2001-02-26 | 2004-10-15 | Optinose As | Nasal devices. |
GB0207422D0 (en) | 2002-03-28 | 2002-05-08 | Optinose As | Nasal devices |
GB0207817D0 (en) | 2002-04-04 | 2002-05-15 | Optinose As | Nasal devices |
GB0209494D0 (en) | 2002-04-25 | 2002-06-05 | Optinose As | Nasal devices |
GB0215270D0 (en) | 2002-07-02 | 2002-08-14 | Optinose As | Nasal devices |
GB0215904D0 (en) | 2002-07-09 | 2002-08-21 | Team Holdings Uk Ltd | Drug delivery system and method |
GB0300008D0 (en) | 2003-01-02 | 2003-02-05 | Optinose As | Delivery devices |
GB0311570D0 (en) | 2003-05-20 | 2003-06-25 | Optinose As | Delivery device and method |
GB0319119D0 (en) | 2003-08-14 | 2003-09-17 | Optinose As | Delivery devices |
GB0320171D0 (en) | 2003-08-28 | 2003-10-01 | Optinose As | Delivery devices |
USD530815S1 (en) | 2004-03-19 | 2006-10-24 | Optinose As | Nasal delivery device |
GB0420513D0 (en) | 2004-09-15 | 2004-10-20 | Optinose As | Powder delivery devices |
GB0503738D0 (en) | 2005-02-23 | 2005-03-30 | Optinose As | Powder delivery devices |
AU2006335994A1 (en) | 2006-01-19 | 2007-07-26 | Optinose As | Nasal administration |
GB0602980D0 (en) | 2006-02-14 | 2006-03-29 | Optinose As | Delivery device and method |
US8171929B2 (en) | 2006-02-14 | 2012-05-08 | Optinose As | Delivery device and method |
GB0604319D0 (en) | 2006-03-03 | 2006-04-12 | Optinose As | Nasal delivery |
GB0604444D0 (en) | 2006-03-06 | 2006-04-12 | Optinose As | Nasal devices |
GB0605799D0 (en) | 2006-03-23 | 2006-05-03 | Optinose As | Nasal delivery devices |
GB2437488A (en) | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
GB2438834A (en) | 2006-06-08 | 2007-12-12 | Optinose As | Intranasal protein administration |
GB2440316A (en) | 2006-07-25 | 2008-01-30 | Optinose As | Nasal inhaler with scrubber |
WO2008067254A2 (en) | 2006-11-27 | 2008-06-05 | Abbott Respiratory Llc | Nasal drug delivery device and method |
GB0623731D0 (en) | 2006-11-28 | 2007-01-10 | Optinose As | Delivery device |
GB0623732D0 (en) | 2006-11-28 | 2007-01-10 | Optinose As | Powder delivery devices |
GB0623728D0 (en) | 2006-11-28 | 2007-01-10 | Optinose As | Delivery devices |
WO2008122018A1 (en) * | 2007-04-02 | 2008-10-09 | Abbott Respiratory Llc | Breath actuated nasal pump |
GB2448193A (en) | 2007-04-05 | 2008-10-08 | Optinose As | Nasal delivery device |
GB2448183A (en) | 2007-04-05 | 2008-10-08 | Optinose As | Nasal powder delivery device |
GB2471973B (en) | 2007-10-03 | 2012-03-14 | Optinose As | Nasal delivery devices |
US20110318345A1 (en) | 2008-09-15 | 2011-12-29 | Optinose As | Nasal delivery |
EP2210580B1 (fr) * | 2009-01-27 | 2019-03-06 | Laboratoire de la Mer | Canule pour l'administration d'une solution fluide dans une narine |
GB201015371D0 (en) | 2010-09-14 | 2010-10-27 | Optinose As | Nasal delivery |
US9949923B2 (en) | 2011-03-15 | 2018-04-24 | Optinose As | Nasal delivery |
PL2817054T3 (pl) | 2012-02-24 | 2020-12-14 | Optinose As | Donosowe urządzenia podające |
KR20150004327A (ko) | 2012-02-24 | 2015-01-12 | 옵티노즈 에이에스 | 경비 투여 장치 |
EP2817053B1 (en) | 2012-02-24 | 2018-05-30 | Optinose AS | Nasal delivery devices |
PL2978482T3 (pl) | 2013-03-26 | 2022-10-03 | Optinose As | Podawanie donosowe |
US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
USD725769S1 (en) | 2013-05-23 | 2015-03-31 | Optinose As | Nasal delivery device |
USD723156S1 (en) | 2013-05-23 | 2015-02-24 | Optinose As | Nasal delivery device |
-
2013
- 2013-02-25 EP EP13711301.5A patent/EP2817053B1/en active Active
- 2013-02-25 CN CN201380021179.2A patent/CN104428024B/zh active Active
- 2013-02-25 MX MX2014010146A patent/MX358062B/es active IP Right Grant
- 2013-02-25 WO PCT/EP2013/053748 patent/WO2013124493A1/en active Application Filing
- 2013-02-25 US US14/380,836 patent/US10179216B2/en active Active
- 2013-02-25 PL PL13711301T patent/PL2817053T3/pl unknown
- 2013-02-25 IN IN7610DEN2014 patent/IN2014DN07610A/en unknown
- 2013-02-25 ES ES13711301.5T patent/ES2683865T3/es active Active
- 2013-02-25 DK DK13711301.5T patent/DK2817053T3/en active
- 2013-02-25 RU RU2014138492A patent/RU2644293C2/ru active
- 2013-02-25 CA CA2865355A patent/CA2865355C/en active Active
- 2013-02-25 JP JP2014558147A patent/JP6382723B2/ja active Active
-
2015
- 2015-06-30 HK HK15106230.0A patent/HK1207010A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020046751A1 (en) * | 2000-04-14 | 2002-04-25 | John Macrae | Nasal inhaler |
CN200994915Y (zh) * | 2006-12-27 | 2007-12-26 | 游世规 | 一种鼻腔清洗器 |
CN101918061A (zh) * | 2007-10-03 | 2010-12-15 | 奥普蒂诺斯公司 | 鼻腔递送装置 |
WO2011153406A2 (en) * | 2010-06-04 | 2011-12-08 | The Government of the United States of America as represented by the Secretary of Health and Human Services, Centers for Disease Control and Prevention | Nasal aerosol delivery system |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114602046A (zh) * | 2022-05-10 | 2022-06-10 | 纳索菲德(上海)制药技术有限公司 | 向鼻腔嗅区递送药液的装置及其使用方法 |
Also Published As
Publication number | Publication date |
---|---|
RU2014138492A (ru) | 2016-04-10 |
ES2683865T3 (es) | 2018-09-28 |
CA2865355C (en) | 2021-02-16 |
CN104428024B (zh) | 2018-06-01 |
EP2817053A1 (en) | 2014-12-31 |
US10179216B2 (en) | 2019-01-15 |
RU2644293C2 (ru) | 2018-02-08 |
CA2865355A1 (en) | 2013-08-29 |
PL2817053T3 (pl) | 2019-01-31 |
US20150246194A1 (en) | 2015-09-03 |
JP6382723B2 (ja) | 2018-08-29 |
WO2013124493A1 (en) | 2013-08-29 |
MX2014010146A (es) | 2015-10-22 |
IN2014DN07610A (zh) | 2015-05-15 |
MX358062B (es) | 2018-08-03 |
JP2015507991A (ja) | 2015-03-16 |
EP2817053B1 (en) | 2018-05-30 |
DK2817053T3 (en) | 2018-08-13 |
HK1207010A1 (zh) | 2016-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104428024A (zh) | 鼻部递送装置 | |
US20220152324A1 (en) | Nasal delivery devices | |
US20220096763A1 (en) | Nasal delivery | |
EP1363692B1 (en) | Nasal delivery devices | |
US8171929B2 (en) | Delivery device and method | |
EP1996266A2 (en) | Nasal delivery | |
WO2012123819A1 (en) | Nasal delivery | |
GB2397025A (en) | Devices to deliver substances to the mucosa of the nose or mouth | |
AU2008202441B2 (en) | Nasal devices | |
GB2414414A (en) | Nasal delivery devices | |
GB2405800A (en) | Nasal delivery devices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221028 Address after: Pennsylvania, America Patentee after: Aptinos Co.,Ltd. Address before: Oslo Patentee before: OptiNose A/S |
|
TR01 | Transfer of patent right |